News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
730,237 Results
Type
Article (41352)
Company Profile (265)
Press Release (688603)
Multimedia
Podcasts (92)
Webinars (20)
Section
Business (204851)
Career Advice (2031)
Deals (35581)
Drug Delivery (128)
Drug Development (81513)
Employer Resources (173)
FDA (16504)
Job Trends (14979)
News (346820)
Policy (32753)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2594)
Accelerated approval (46)
Adcomms (26)
Allergies (170)
Alliances (49585)
ALS (210)
Alzheimer's disease (1782)
Antibody-drug conjugate (ADC) (440)
Approvals (16876)
Artificial intelligence (652)
Autoimmune disease (280)
Automation (54)
Bankruptcy (362)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (219)
Biotechnology (175)
Bladder cancer (186)
Brain cancer (71)
Breast cancer (743)
Cancer (5759)
Cardiovascular disease (466)
Career advice (1723)
Career pathing (41)
CAR-T (329)
CDC (56)
Celiac Disease (3)
Cell therapy (886)
Cervical cancer (47)
Clinical research (70741)
Collaboration (2032)
Company closure (5)
Compensation (1381)
Complete response letters (78)
COVID-19 (2740)
CRISPR (107)
C-suite (1106)
Cystic fibrosis (151)
Data (7759)
Decentralized trials (3)
Denatured (27)
Depression (159)
Dermatology (83)
Diabetes (584)
Diagnostics (6916)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (314)
Drug pricing (200)
Drug shortages (31)
Duchenne muscular dystrophy (280)
Earnings (91914)
Editorial (66)
Employer branding (21)
Employer resources (152)
Events (119366)
Executive appointments (1075)
FDA (20193)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (16)
Frontotemporal dementia (34)
Funding (1704)
Gene editing (232)
Generative AI (55)
Gene therapy (712)
GLP-1 (1049)
Government (4730)
Grass and pollen (6)
Guidances (408)
Healthcare (18987)
HIV (79)
Huntington's disease (56)
IgA nephropathy (96)
Immunology and inflammation (285)
Immuno-oncology (91)
Indications (189)
Infectious disease (3078)
Inflammatory bowel disease (216)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (288)
Interviews (319)
IPO (16667)
IRA (50)
Job creations (3646)
Job search strategy (1430)
JPM (58)
Kidney cancer (19)
Labor market (98)
Layoffs (562)
Leadership (38)
Legal (7954)
Liver cancer (99)
Longevity (32)
Lung cancer (758)
Lymphoma (427)
Machine learning (59)
Management (59)
Manufacturing (1029)
MASH (183)
Medical device (13918)
Medtech (14036)
Mergers & acquisitions (20153)
Metabolic disorders (1485)
mRNA (203)
Multiple sclerosis (187)
NASH (17)
Neurodegenerative disease (411)
Neuropsychiatric disorders (105)
Neuroscience (3278)
Neurotech (1)
NextGen: Class of 2026 (6521)
Non-profit (4530)
Now hiring (77)
Obesity (696)
Opinion (286)
Ovarian cancer (218)
Pain (250)
Pancreatic cancer (294)
Parkinson's disease (356)
Partnered (33)
Patents (592)
Patient recruitment (665)
Peanut (62)
People (59549)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (22049)
Phase 2 (31162)
Phase 3 (23194)
Pipeline (8469)
Policy (313)
Postmarket research (2568)
Preclinical (9392)
Press Release (64)
Prostate cancer (293)
Psychedelics (54)
Radiopharmaceuticals (319)
Rare diseases (1064)
Real estate (5968)
Recruiting (70)
Regulatory (25359)
Reports (56)
Research institute (2414)
Resumes & cover letters (353)
Rett syndrome (38)
RNA editing (21)
RSV (88)
Schizophrenia (176)
Series A (286)
Series B (211)
Service/supplier (11)
Sickle cell disease (111)
Special edition (23)
Spinal muscular atrophy (165)
Sponsored (48)
Startups (3638)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (63)
Vaccines (1089)
Venture capital (107)
Weight loss (448)
Women's health (124)
Worklife (20)
Date
Today (211)
Last 7 days (923)
Last 30 days (3430)
Last 365 days (30244)
2026 (11942)
2025 (30174)
2024 (35217)
2023 (40076)
2022 (51181)
2021 (55707)
2020 (54088)
2019 (46542)
2018 (35016)
2017 (32109)
2016 (31479)
2015 (37551)
2014 (31318)
2013 (26347)
2012 (28570)
2011 (29264)
2010 (27330)
Location
Africa (741)
Alabama (92)
Alaska (7)
Arizona (347)
Arkansas (14)
Asia (39653)
Australia (6500)
California (13135)
Canada (3725)
China (1323)
Colorado (563)
Connecticut (571)
Delaware (400)
Europe (85792)
Florida (1963)
Georgia (420)
Hawaii (3)
Idaho (62)
Illinois (1044)
India (88)
Indiana (596)
Iowa (23)
Japan (529)
Kansas (130)
Kentucky (50)
Louisiana (40)
Maine (75)
Maryland (1576)
Massachusetts (9370)
Michigan (359)
Minnesota (708)
Mississippi (6)
Missouri (144)
Montana (33)
Nebraska (29)
Nevada (140)
New Hampshire (84)
New Jersey (3454)
New Mexico (29)
New York (3433)
North Carolina (1665)
North Dakota (9)
Northern California (6575)
Ohio (393)
Oklahoma (23)
Oregon (41)
Pennsylvania (2639)
Puerto Rico (29)
Rhode Island (50)
South America (1112)
South Carolina (85)
South Dakota (2)
Southern California (5181)
Tennessee (209)
Texas (2084)
United States (46334)
Utah (392)
Vermont (1)
Virginia (317)
Washington D.C. (80)
Washington State (1052)
West Virginia (4)
Wisconsin (124)
Wyoming (2)
730,237 Results for "immunome inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2026
May 6, 2026
·
1 min read
Press Releases
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
April 22, 2026
·
4 min read
Press Releases
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
April 29, 2026
·
6 min read
Cancer
Immunome Heads to the FDA With Desmoid Tumor Drug After Phase III Sweep
Varegacestat, a gamma secretase inhibitor, significantly improved progression-free survival while also meeting all key secondary endpoints in the pivotal RINGSIDE trial. Immunome is planning an FDA application for the second quarter of 2026.
December 15, 2025
·
2 min read
·
Heather McKenzie
Press Releases
Immunome to Present at Upcoming March 2026 Investor Conferences
February 23, 2026
·
1 min read
Press Releases
Immunome Reports Full Year 2025 Financial Results and Provides Business Update
March 4, 2026
·
9 min read
Press Releases
Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
February 5, 2026
·
1 min read
Press Releases
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 5, 2026
March 5, 2026
·
1 min read
Press Releases
Immunome Announces Pricing of Public Offering of Common Stock
December 17, 2025
·
4 min read
Press Releases
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
·
1 min read
1 of 73,024
Next
